- in critical condition or has ards - on invasive mechanical ventilation or ecmo - bacterial or fungal infection - pregnant or lactating (women) - alt >5x uln, bilirubin >2x uln, inr outside of normal limits at screening - egfr <30 ml/min - clinically relevant serious co-morbid medical conditions - treatment with any immunosuppressive therapy within 30 days prior to screening - treatment with another investigational drug within 30 days or 5 half-lives of drug prior to screening - prior treatment with the study drug (mmpd) or treatment with remdesivir more than 24 hours prior to the first randomized dose of study drug - known hypersensitivity to the inactive ingredients in the study drug (mmpd or placebo) or any ingredient of remdesivir

- in critical condition or has ards - on invasive mechanical ventilation or ecmo - bacterial or fungal infection - pregnant or lactating (women) - alt >5x uln, bilirubin >2x uln, inr outside of normal limits at screening - egfr <30 ml/min - clinically relevant serious co-morbid medical conditions - treatment with any immunosuppressive therapy within 30 days prior to screening - treatment with another investigational drug within 30 days or 5 half-lives of drug prior to screening - prior treatment with the study drug (mmpd) or treatment with remdesivir more than 24 hours prior to the first randomized dose of study drug - known hypersensitivity to the inactive ingredients in the study drug (mmpd or placebo) or any ingredient of remdesivir